MANAGE C1‑INH DEFICIENCY WITH HAEGARDA

HAEGARDA replaces missing or dysfunctional C1‑INH, regulating the normal production of bradykinin

  • Functional C1‑INH levels ≥40% are proposed to reduce the risk of HAE attacks1
  • The 2017 World Allergy Organization Guidelines recommend use of C1 esterase inhibitors for first-line, long-term prophylaxis2
Functional C1-INH level. Relative risk for an HAE attack.

SUBCUTANEOUS C1‑INH BUILDS AND MAINTAINS STEADY‑STATE C1‑INH FUNCTIONAL ACTIVITY*3

Administered subcutaneously, HAEGARDA 60 IU/kg maintained steady-state C1‑INH functional levels above 40%3

HAEGARDA 60 IU/kg Administered Subcutaneously3
  • Steady state is expected within 3 to 4 doses1

*The plasma levels of C1‑INH functional activity were evaluated in patients with type 1 or type 2 HAE in a Phase 3, placebo‑controlled, crossover study. Patients received twice-weekly subcutaneous injections of HAEGARDA 40 IU/kg or 60 IU/kg for 16 weeks. The model-derived outcome is the steady-state C1‑INH functional activity vs time.3

IN-HOME NURSE TRAINING THROUGH HAEGARDA CONNECTSM

HAEGARDA Connect offers your HAE patients in-home training to educate on safe practices and help get them comfortable with preparing and injecting HAEGARDA. This training is available at no cost to the patient. LEARN MORE

You are now leaving the current website.